IBB
Hold itCreating symmetrical inverted H&S, which is a good thing. Needs to hold above low of left shoulder. Added at $8.91
UpdatedUpdated Opko Health Chart. Still in inverted H&S. Looking to break out of falling wedge on right shoulder.
Weekly chart finding support a 50% retracementWe are seeing organized accumulation at the 50% retracement which mean the overall trend for IBB remains intact and bullish. Failure to hold the 50% threshold would suggest that prices could breakdown to $200. In the meantime demand is contracting on this smaller timeframe rally. This will likely result in a re-test and confirmation of this level following any potential break. If a re-test happens on light volume this is an ideal long entry. If the re-test is on greater than average selling volume watch out below.
Showing signs of accumlation but has to close above $290Bullish above $290. Buyer of $270 as risk is well defined
IBB has been under accumulation for most of 2016. This is try because both the monthly and weekly vertical bar/candle stick charts are in distribution. In other words this smaller timeframe is in accumulation and upon testing $320 will likely encounter longer timeframe supply and continue to break down and test $240.
We can see selling volume contract on the re-test of lows followed by an increase in buying demand. Note; however, they buying volume is contracting into resistance of $290. It is reasonable to anticipate that prices will pullback and test $270 where I suspect strong hands will resume control and push price discovery higher.
Good Luck
Ripe for BOBullish divergences in the MACD & MFI from Jan. Extended to Inverted H&S, buy point $12.17.
ContinuousStrong extension of inverted Head & Shoulders. Breakout over $11.85 will clear the neckline and commence through.
Reversal ConfirmedDouble Bottom, Oversold Condition, MACD turning up, beat Rev by+9% and EPS by +33%
Signs of Life to $62Very strong Weekly MACD bullish crossover and RSI reversal at oversold conditions.
Inverted H&S BullishSee image for inverted H&S. Buy point was 10.3. Biotech is next in sector rotation